The Wall Street Journal reports that Johnson & Johnson’s fourth-quarter earnings fell 89% following settlements for misrepresenting the risks and benefits of Risperdal, its once top-selling drug.
Read moreDiscuss →
***
Mad in America hosts blogs by a diverse group of writers. These posts are designed to serve as a public forum for a discussion—broadly speaking—of psychiatry and its treatments. The opinions expressed are the writers’ own.
